Drug-like analogues of the parasitic worm-derived immunomodulator ES-62 are therapeutic in the MRL/Lpr model of systemic lupus erythematosus.

PubWeight™: 0.77‹?›

🔗 View Article (PMC 4616909)

Published in Lupus on June 17, 2015

Authors

D T Rodgers1, M A Pineda1, C J Suckling2, W Harnett3, M M Harnett4

Author Affiliations

1: Institute of Infection, Immunity and Inflammation, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, UK.
2: Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow, UK.
3: Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
4: Institute of Infection, Immunity and Inflammation, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, UK Margaret.Harnett@glasgow.ac.uk W.Harnett@strath.ac.uk.

Articles cited by this

Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol (2010) 3.69

The parasitic helminth product ES-62 suppresses pathogenesis in collagen-induced arthritis by targeting the interleukin-17-producing cellular network at multiple sites. Arthritis Rheum (2012) 3.16

Autoimmunity: The worm returns. Nature (2012) 1.77

Helminth-derived immunomodulators: can understanding the worm produce the pill? Nat Rev Immunol (2010) 1.66

Signals via the adaptor MyD88 in B cells and DCs make distinct and synergistic contributions to immune activation and tissue damage in lupus. Immunity (2013) 1.40

Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice. Arthritis Rheum (2007) 1.37

Signaling through the adaptor molecule MyD88 in CD4+ T cells is required to overcome suppression by regulatory T cells. Immunity (2014) 1.16

Designing anti-inflammatory drugs from parasitic worms: a synthetic small molecule analogue of the Acanthocheilonema viteae product ES-62 prevents development of collagen-induced arthritis. J Med Chem (2013) 1.13

Requirement for MyD88 signaling in B cells and dendritic cells for germinal center anti-nuclear antibody production in Lyn-deficient mice. J Immunol (2013) 1.09

Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases. Pharmacol Ther (2013) 1.00

MyD88-dependent interplay between myeloid and endothelial cells in the initiation and progression of obesity-associated inflammatory diseases. J Exp Med (2014) 0.98

Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients. Rheumatology (Oxford) (2010) 0.97

Mediators of inflammation and their effect on resident renal cells: implications in lupus nephritis. Clin Dev Immunol (2013) 0.95

Future prospects in biologic therapy for systemic lupus erythematosus. Nat Rev Rheumatol (2013) 0.93

The parasitic worm product ES-62 targets myeloid differentiation factor 88-dependent effector mechanisms to suppress antinuclear antibody production and proteinuria in MRL/lpr mice. Arthritis Rheumatol (2015) 0.86